Despite multiple trials of new agents in advanced non-small-cell lung cancer (NSCLC), outcomes remain poor. This study explores how the design and interpretation of randomized trials in advanced NSCLC has changed over time.
INTRODUCTION
Advanced non-small-cell lung cancer (NSCLC) is among the most intractable solid tumors. Its aggressiveness paired with a high prevalence have rendered it the leading cause of cancer-related death.
1,2 As such, it has been the subject of extensive investigation over several decades in order to develop effective treatments. These efforts have yielded first-and second-line chemotherapy [3] [4] [5] [6] [7] [8] [9] [10] [11] and targeted therapy for selected subpopulations 12, 13 or as third-line after chemotherapy failure.
14 However, the clinical benefit of these treatments has been modest.
Phase III clinical trials have been the primary vehicle by which these treatments have been shown to have a clinically meaningful and statistically significant impact on patient outcomes. As interest in NSCLC from the oncology community and pharmaceutical industry has grown, changes in both the design and interpretation of these trials have begun to emerge with respect to statistical power, sample size, and the primary end points used. There has been ongoing debate regarding oncology clinical trial design, including the use of progression-free survival (PFS) in lieu of overall survival as a primary study end point. [15] [16] [17] [18] The use of PFS as a primary study end point has been promoted on the basis of an increasing use of crossover in clinical trials as well as an increasing number of lines of subsequent treatment. The US Food and Drug Administration has recently accepted PFS as a potential primary study end point for drug approval in advanced NSCLC but
has noted reservations regarding the accuracy, reproducibility, and clinical relevance of this end point. 19 Critics of PFS as a primary study end point have questioned the potential subjectivity of this end point with respect to the frequency of radiographic surveillance as well as its relationship to clinically relevant outcomes such as quality of life and overall survival. 17, 19 The definition of clinically meaningful benefit in trials of new agents in advanced cancer continues to be debated, particularly with respect to emerging end points such as PFS. [20] [21] [22] [23] [24] The increasing number of systemic therapies available paired with escalating treatment costs have further fueled this discussion.
Apart from changes in the design of clinical trials, the manner in which these trials are interpreted may be changing as well. An increasing willingness to interpret the results of clinical trials as positive despite extremely modest or questionable benefit of a new treatment has been previously reported. This trend appears to be influenced by numerous factors, including potential trial funding sources and statistical knowledge.
25,26
Thus, we have sought to investigate these trends in clinical trial design and interpretation in advanced NSCLC. Here we report a review of all phase III trials conducted in advanced NSCLC over the past three decades, examining changes over time in the primary end point, sample size, interpretation, and magnitude of benefit described in advanced NSCLC clinical trials.
METHODS
An extensive literature search for all phase III randomized controlled clinical trials involving systemic therapy for advanced NSCLC was performed by using the PubMed clinical queries application (Data Supplement). Professional oncology society guidelines were screened to identify studies missed in the aforementioned search strategy (Data Supplement). Studies were eligible for inclusion if they were phase III, involved systemic therapy only, studied patients with advanced NSCLC, and were conducted between 1980 and 2010. For eligible studies (Data Supplement), the following were abstracted: publication date, size, primary and secondary outcomes, trial outcome (positive or negative), statistical significance, and the magnitude of clinical benefit in terms of the primary outcome measure (ie, absolute difference in benefit between treatment arms). Trials were deemed positive if the authors recommended the new treatment arm be adopted on any basis or studied further. This was determined by the investigators on the basis of direct scrutiny of the study text for an explicit statement of either a recommendation for adopting the study treatment into practice or recommendation of further study of the experimental treatment. Trials were scored as positive if either of these explicit statements was found. Positive trial interpretation was recorded as a distinct entity from trial outcome with respect to statistical significance. Trials were further classified as asserting noninferiority if the authors explicitly stated that the study agent was either equal in efficacy or noninferior to the control arm. Trials were categorized by publication year, including those published between 1980 and 1990, 1991 and 2000, and 2001 and 2010. Descriptive statistics were used to summarize the patterns in trial design, primary outcome, reported statistical significance, and magnitude of net survival benefit by each time period. The Cochran-Armitage trend test was used to test the change over the time periods in reporting the primary outcomes, trial conclusions, and statistical significances. The F test was used to test the change over time in reported net survival benefit and trial size. The net survival benefit is defined as the difference in median survival time between the experimental arm and the control arm. A log transformation was used to achieve approximate normal before the F test. Analysis was carried out by using SAS v9.3 (SAS Institute, Cary, NC).
RESULTS
In all, 248 trial reports were identified, and their full text was reviewed by the authors. Forty-five were excluded because they involved smallcell lung cancer (n ϭ 3), earlier-stage NSCLC (n ϭ 5), surgery or radiotherapy (n ϭ 6), were not phase III trials (n ϭ 13), or were subgroup/interim analyses of studies already included (n ϭ 18). A total of 203 unique trials were included in our study.
Patterns in Trial Design: Sample Size and Primary End Point
Detailed review of the 203 trials revealed several trends over time. The number of phase III trials conducted in advanced NSCLC has increased dramatically-32 trials were conducted in the 1980s compared with 53 trials in 1990s and 118 trials in the most recent decade (Table 1) . At the same time, the sample size of advanced NSCLC trials has also increased, from a median of 152 patients (range, 38 to 743 patients) in the 1980s to 184 patients (range, 58 to 680 patients) in the 1990s and 413 patients (range, 58 to 1,725 patients) in 2001 to 2010 (P Ͻ .001). The distribution of treatments being studied has also shifted from a heavy emphasis on multiagent triplet chemotherapy in the 1980s to predominantly doublet therapy in the 1990s and a sizeable increase in studies of targeted therapy in 2001 to 2010 (Table 1) .
There has been a significant shift in the primary end point of phase III advanced NSCLC trials. Before 2000, almost all studies were designed with overall survival as the primary end point, most commonly reported as the median overall survival time (97% in 1980 to 1990; 96% in 1991 to 2000). Significantly fewer trials used overall survival as the primary end point in the period between 2001 and 2010 (81%; P Ͻ .002), with a clear increase in the use of PFS as the primary study end point instead (13%).
Interpretation of Trials
Interpretation of trial results in advanced NSCLC is also shifting over time. This is exemplified by the significant increase in the number of trials reporting a positive result, as defined by recommendation for treatment adoption or for further study (Table 1 . These trials were recommended on the basis of improvements seen in secondary trial end points (PFS, toxicity; n ϭ 24), asserting noninferiority despite lack of a statistically appropriate noninferiority design (n ϭ 26), or recommending further study on the basis of a nonsignificant trend in primary outcome (n ϭ 9). Interestingly, the period from 1980 to 1990 was the only one in which studies that met their statistical primary end point were declared negative because of the insufficient magnitude of clinical benefit (n ϭ 2).
Clinical Benefit in Positive Trials
The final dimension examined was the magnitude of clinical benefit using the median survival time as the primary outcome. In the 60 trials reporting statistically significant survival improvement, the median net survival benefit was 3.9 months (range, 1.7 to 7. Fig  1) . Interestingly, despite the decreasing magnitude of clinical benefit in these trials over time, the average median survival across trials in each time period has increased from 6.7 months in 1980 to 1990 to 9.5 months in 2001 to 2010 (Table 1) .
DISCUSSION
This study reveals important changes that have occurred in phase III clinical trials in advanced NSCLC over the past 30 years. The size of trials has increased significantly alongside a decline in the use of overall survival in favor of PFS as the primary study end point. The average overall survival of patients in these trials has modestly but progressively increased over time. The number of trials reporting a positive outcome has also increased significantly. This is largely because of a growing number of studies recommending new agents on the basis of statistically nonsignificant trends in the primary end point, such as noninferiority without appropriate statistical testing, or benefit in secondary end points like toxicity. A similar trend toward increasingly positive interpretations of clinical trial outcomes has been identified in other areas of oncology-related clinical research and in research not related to oncology. Previously, this has been attributed to lack of statistical rigor and knowledge, increasing pressure for clinical trials to produce some positive result, and the influence of industry-related funding. 
25,26
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Publication Time Period The increasing use of PFS as a surrogate for overall survival in advanced NSCLC trials also has the potential to further obfuscate the clinical benefit of newer agents in terms of those outcomes most important to people with advanced cancer: overall survival, quality of life, and symptom control. [15] [16] [17] [18] The increasing popularity of PFS as a primary study end point can be attributed to both an increasing willingness on the part of regulatory authorities to accept it and an increasing use of cross-over trial designs and subsequent lines of treatment that may complicate the demonstration of an overall survival benefit.
19 However, the importance of demonstrating that PFS translates into meaningful clinical benefit for patients cannot be understated, given concerns regarding the potential subjectivity and variability of this end point, particularly when the magnitude of PFS benefit is small. 17, 19 Our findings confirm a disquieting shift in phase III trial design in advanced NSCLC. Despite the advances in design through larger size and statistical power over the past three decades, the bar for judging clinical benefit of new agents in lung cancer appears to be falling. Although larger trials are more adept at detecting small differences in survival benefit between treatment arms, the oncology community relies on investigators to define the minimum magnitude of clinical benefit, or minimum clinically important difference, to ascertain the value of a new agent in advanced cancer. It appears that investigators are progressively less stringent in deeming treatments of value even when the statistically significant advantage achieved is no longer clinically relevant. This distinction is particularly important in light of the increasing cost of conducting larger trials and approving new agents with modest benefit, as well as the overall poor prognosis of patients with advanced NSCLC.
21-24
The number of trials that recommend adoption or further study of a new agent despite the initial trial not meeting its primary statistical end point has clearly increased over time. Although this may be in part related to modest benefits in secondary end points, including toxicity or presumed noninferiority, there may be additional biases at play. With advances in personalized medicine, there is a belief that an agent with a clinically insignificant benefit is a reflection of an insufficiently selected population rather than insufficient drug activity. Publication bias or trial sponsorship may also play a role in investigator conclusions regarding trials. Positive trials remain more likely to be published, no matter how important the negative result may be to the oncology community.
These findings raise questions regarding the design and interpretation of phase III trials in advanced NSCLC. The intention of multiphase clinical trials is to focus resources on promising agents, with each phase eliminating either toxic or minimally active agents. Our results suggest that we are progressively less efficient in accomplishing this task in advanced NSCLC trials. Clear standards of acceptable minimal clinical differences in advanced NSCLC and appropriate clinically relevant outcomes should be established and endorsed. Previous recommendations on the minimal relevant clinical benefit have varied greatly. 24, 27 We believe the proposals to raise the bar of minimal clinical benefit to a 50% improvement in the current overall survival and doubling of PFS to be particularly promising. 24 A renewed focus on earlier-phase trials designed to detect clinically important differences in treatment before proceeding to large phase III trials and greater study of the validity of surrogate end points such as PFS may help. 21, 24 Encouraging smaller earlier-phase trials designed to detect clinically significant benefit from new agents will speed development of new, more effective drugs. This will also encourage a greater emphasis on early biomarker development and patient selection where appropriate in order to optimize benefit in these trials. 24 If we can alter these trends in trial design and interpretation, there is great potential to minimize trial and drug development costs on marginally effective, or ineffective, agents.
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